News

08.03.20

Press Release

Achieve Life Sciences Announces Proposed Public Offering

SEATTLE, Wash. and VANCOUVER, British Columbia, August 3. 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock…

/Read More

07.31.20

Press Release

Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications

SEATTLE, Wash and VANCOUVER, British Columbia, July 31, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (US 2020/0172544 A1) on novel analogs of cytisinicline,…

/Read More

07.28.20

Press Release

Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

SEATTLE, Wash. and VANCOUVER, British Columbia, July 28, 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020. Company management will host a conference call and live webcast at 4:30…

/Read More

06.29.20

Press Release

Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering

SEATTLE, Wash. and VANCOUVER, British Columbia, June 29, 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and…

/Read More

06.29.20

Press Release

Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix (varenicline) as a Treatment to Quit Smoking

Cytisinicline demonstrated quit rates at least as effective as varenicline Participants on cytisinicline experienced significantly fewer side effects than those on varenicline SEATTLE, Wash and VANCOUVER, British Columbia, June 29, 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and…

/Read More